Biggest News Aggregation in the World
📰 Efficacy Endpoint News

Efficacy Endpoint News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Efficacy Endpoint. Real-time updates on events, politics, business and more.

Formycon's Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product S

DGAP-News: Formycon AG / Key word(s): Study results/StudyFormycon's Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara®* in Phase III Study 16.08.2022 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.Press Release // August 16, 202...
United States Formycon Biosimilar Ustekinumab Stefan Glombitza Corporate Communications Distribution Services Comparable Efficacy

DGAP-News: Formycon's Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara* in Phase III Study Seite 1

16.08.2022 - DGAP-News: Formycon AG / Key word(s): Study results/Study Formycons Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara* in Phase III Study 16.08.2022 / 07:30 CET/CEST The issuer is solely responsible ... Seite 1
Formycon Biosimilar Ustekinumab Stelara Ustekinumab Biosimilar Ustekinumab Candidate Comparable Efficacy Reference Product Efficacy Endpoint

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2b Clinical Trial Evaluating Novel Suvecaltamide (JZP385) for Once-Daily Treatment of Adults with Essential Tremor

DUBLIN, Dec. 15, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in a global Phase 2b clinical trial evaluating the safety
United States United Kingdom Marka Goldstein Kristin Bhavnani Patrick Mccartney Andrean Flynn

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science